PPARG and gastric adenocarcinoma: Also, a study with 277 patients showed that the presence of the prostaglandin PGD2 reduces tumor expansion of gastric adenocarcinoma by inhibiting the peroxisome proliferator-activated receptor gamma (PPARγ) pathway [36].